Johnson & Johnson’s (JNJ) – Get the report the single-shot Covid-19 vaccine appears to be two months behind schedule in the original production schedule and will not be updated until late April.
Citing people familiar with the matter, The New York Times reported that while Johnson & Johnson hopes to publish the results of its trial of the Covid-19 vaccine in just two weeks, production will likely face delays in due to delays in vaccine manufacturing from the door to April.
The delays come as the United States continues to face records of infections, hospitalizations and deaths from the new coronavirus, which has so far infected some 91.6 million people, causing more than 1, 96 million dead, according to Johns Hopkins University.
More than 4,300 people died from the disease on Tuesday, as the total number of deaths in the nation exceeded 380,000.
Johnson & Johnson chief scientific officer Paul Stoffels told the Times that if the data is positive and the Food and Drug Administration approves the vaccine for emergency use, Johnson & Johnson could contribute to vaccination in United States sometime in March.
However, the apparent lags in Johnson & Johnson’s production capabilities could still hamper efforts to deploy the vaccine and put it to arms. According to federal officials, the company has gone back up to two months from the original production schedule and will not be updated until the end of April, when it was supposed to have administered more than 60 million doses.
If the Johnson & Johnson vaccine can strongly protect people against Covid-19, as some outside scientists hope, it would offer great advantages over the two vaccines currently authorized in the United States, which require more doses and cold storage requirements. complicated.
Pfizer (PFE) – Get the report and BioNTech (BNTX) – Get the report as well as Modern (MRNA) – Get the report they received emergency permission to deploy the vaccines last month.
The US is still delaying its vaccination schedules. As of Tuesday, 27 million vaccines had been distributed, although only 9 million had been administered, according to data from the Centers for Disease Control.
Shares of Johnson & Johnson rose 0.5% to $ 157.34 on Wednesday.